Accuracy of Prefilled "Code Cart" Epinephrine Syringes for Direct Administration of Small Doses
Prefilled syringes offer a convenient way to administer epinephrine to patients experiencing cardiac arrest. Epinephrine is a critical drug that can improve survival in children experiencing cardiac arrest, although very high doses (0.1 mg/kg) of the drug can worsen outcomes. 1, 2 One practice for administering epinephrine during pediatric resuscitation is direct administration of a partial volume from commercially available prefilled syringes. We conducted a study examining the accuracy of direct injection of an infant dose (0.05 mg or 0.5 mL) of epinephrine from prefilled epinephrine syringes using the graduated lines on the syringe. We used the recommended dose in the Pediatric Advanced Life Support algorithm (0.01 mg/kg), although the Neonatal Resuscitation Program includes a range of 0.01 mg/kg to 0.03 mg/kg. We hypothesized that direct injection may yield inaccurate doses.
Methods | We evaluated the accuracy of the 2 types of epinephrine 1:10 000, 1 mg per 10 mL prefilled syringes available for purchase in the United States: LifeShield ABBOJECT (Hospira) and Luer-Jet Luer-Lock (International Medication Systems Ltd).
To determine the actual volume expelled when the plunger was depressed to the 0.5-mL mark of the prefilled syringe, we connected the prefilled syringes to a 1-mL syringe via a flushed 3-way stopcock and depressed the plunger on the epinephrine syringes to the 0.5-mL mark. This simulates direct injection from the syringe into an intravenous port followed by a flush, where 100% of the medication enters the patient and none is lost in tubing or intravenous ports. We recorded the volume delivered to the 1-mL syringe, attaching a new 1-mL syringe if volume exceeded 1 mL. We then measured the total volume in the prefilled syringe by expelling the remaining contents. For each test, at least 2 investigators were present (M.H., N.M., and C.E.) to provide dual verification of volumes.
We conducted 2 additional validation tests. First, we tested the volume when the plunger was depressed to the 0.5-mL mark, expelling the medication into a graduated cylinder. Second, we tested the volume using the weight and density of the medication using an Ohaus EX224N precision scale (Ohaus Corporation). We weighed 1 mL of epinephrine 1:10 000 (1.010 g) and 1 mL of water (1.000 g) using the same syringe. We subsequently weighed each dose of epinephrine expelled by the prefilled syringe when the plunger was depressed to the 0.5-mL mark and then calculated the volume using the density. The Oregon Health & Science University institutional review board reviewed the study and found it was not human subjects research. 
COMMENT & RESPONSE

Acetaminophen in Pregnancy and Adverse Childhood Neurodevelopment
To the Editor JAMA Pediatrics published an observational retrospective longitudinal cohort study by Stergiakouli et al 1 that
examined the associations between acetaminophen use during pregnancy and childhood behavioral problems. 1 In the article, the authors concluded that the results show prenatal exposure to acetaminophen increases the risk of behavioral problems in children. They postulated an intrauterine mechanism because no associations were found from postnatal or partner's use. However, the authors' conclusions dismiss significant increases in the risk of behavioral problems in children associated with partner acetaminophen use. As shown in Table 3 in the article, the partner's acetaminophen use was associated with conduct problems (risk ratio, 1.38; 95% CI, 1.02-1.88). The effect size and number of associated problems increased after adjusting for confounders in eTable 3 in the Supplement, where the partner's acetaminophen use was associated with conduct problems and hyperactivity symptoms in children (adjusted risk ratio, 1.63; 95% CI, 1.11-2.40 and adjusted risk ratio, 1.41; 95% CI, 1.02-1.97, respectively). This association held constant after adjusting for the mother's prenatal use at 18 and 32 weeks, as observed in eTable 5 in the Supplement. Furthermore, partner's use positively affected the association of 3 Strength and Difficulties Questionnaire domains with maternal prenatal acetaminophen use at 32 weeks in eTable 9 in the Supplement (total difficulties, conduct problems, and peer problems) when compared with eTable 6; prenatal use at 32 weeks positively affected the association of emotional symptoms with partner's use when comparing eTable 9 with eTable 7 in the Supplement. All 3 of the Strength and Difficulties Questionnaire domains in eTable 2 that were associated with prenatal acetaminophen use at 32 weeks with confidence intervals greater than 1 (total difficulties, conduct problems, and hyperactivity symptoms) were positively affected after adjusting for maternal postnatal use in eTable 4 of the Supplement. 
